Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01545947
Title Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

lung non-small cell carcinoma

Therapies

Azacitidine + Onatasertib

Erlotinib + Onatasertib

Age Groups: adult
Covered Countries USA | ESP


No variant requirements are available.